Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Cardiac MRI Assessment of Changes in Cardiac Measures and Amyloid Burden During Vutrisiran Treatment

  • By

  • Yousuf Razvi

  • Awais Sheikh

  • Rishi K. Patel

  • Anouk Achten

  • Josephine Mansell

  • Ana Martinez-Naharro

  • Lucia Venneri

  • Philip N. Hawkins

  • James Moon

  • John Vest

  • Sameer Bansilal

  • Satish Eraly

  • Emre Aldinc

  • Brian L. Claggett

  • Scott D. Solomon

  • Julian D. Gillmore

  • Marianna Fontana

  • October 1, 2026

Share

  • 1

    This post hoc analysis assessed longitudinal CMR measures in 43 UK participants with ATTR-CM enrolled in the HELIOS-B trial.

  • 2

    Mixed-model estimates favored vutrisiran over placebo for left and right ventricular ejection fraction and stroke volume.

  • 3

    Vutrisiran was associated with lower left ventricular mass and extracellular volume than placebo in the mixed-model analysis.

  • 4

    At year 3, amyloid regression occurred in 2 of 9 vutrisiran recipients and none of 8 placebo recipients with CMR data.

  • 5

    At 36 months, mean ECV decreased by 0.10% with vutrisiran and increased by 7.86% with placebo among CMR completers.

Original Source(s)

Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI

  • by Yousuf Razvi, Awais Sheikh, Rishi K. Patel, Anouk Achten, Josephine Mansell, Ana Martinez-Naharro, Lucia Venneri, Philip N. Hawkins, James Moon, John Vest, Sameer Bansilal, Satish Eraly, Emre Aldinc, Brian L. Claggett, Scott D. Solomon, Julian D. Gillmore, Marianna Fontana

  • October 1, 2026

Related Content

Machine Learning–Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy

FDA flags potential cardiac risk with evenamide

Four deaths among evenamide-treated patients prompted FDA concerns about possible fatal arrhythmias, although a causal link remains unconfirmed.

Predicting Neonatal Hypoxia in dTGA/IVS Remains Challenging, Heightens Need for High-Risk Delivery Planning

Christopher Lindblade, MD, co-author of a 2026 Journal of the American Society of Echocardiography study, shares how factors seen on fetal echocardiography support the Phoenix Children’s model for performing urgent bedside balloon atrial septostomy for babies with neonatal hypoxia.

  • by

  • October 15, 2026

  • 7 min